Legal status · United States
Is PEG-loxenatide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. PEG-loxenatide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
PEG-loxenatide in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | No FDA approval. Approved in China since 2019 for type 2 diabetes. |
| FDA approval status | Not approved in the United States. Approved in China in 2019 for type 2 diabetes and widely used there. No Western regulatory filing located. |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the PEG-loxenatide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing PEG-loxenatide is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What PEG-loxenatide is
Approved in China in 2019 on two placebo-controlled phase 3 trials in 361 and about 360 patients, where it lowered glycated haemoglobin about 1.0 to 1.3 percentage points. Its weight effect in those registration trials was small; the large weight figures come from later single-centre trials at doses well above the licensed ones.
Polyethylene glycol loxenatide, usually written PEX168 in the trial literature, is a PEGylated analogue of exendin-4 from Hansoh Pharmaceutical. It was approved in China in 2019, which makes it one of the earliest domestically developed weekly GLP-1 agonists to reach a market anywhere.
Mechanism: An analogue of exendin-4 modified with polyethylene glycol at a defined site. PEGylation increases molecular size and slows renal clearance, converting a peptide that would need twice-daily injection into a once-weekly one.
Regulatory history: Not approved in the United States. Approved in China in 2019 for type 2 diabetes and widely used there. No Western regulatory filing located.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for PEG-loxenatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
PEG-loxenatide in other countries
Frequently asked questions
Is PEG-loxenatide legal in the United States?
No. PEG-loxenatide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: No FDA approval. Approved in China since 2019 for type 2 diabetes.
Can I buy PEG-loxenatide in the United States?
No approved product exists to buy. In the United States PEG-loxenatide is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: No FDA approval. Approved in China since 2019 for type 2 diabetes.
Is PEG-loxenatide FDA approved?
No. FDA status: Not approved in the United States. Approved in China in 2019 for type 2 diabetes and widely used there. No Western regulatory filing located.. Current US classification: "Not approved; research use only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for PEG-loxenatide live on its compound profile.
PEG-loxenatide profileThis page is general information about the regulatory status of PEG-loxenatide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.